Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?

You might call it a "Pfizzle."In late 2021, Pfizer (PFE 0.70%) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.It followed that success with the launch of an effective oral COVID pill. Both became megablockbusters, with the vaccine (Comirnaty) generating global sales of $37.8 billion and the antiviral therapy (Paxlovid) raking in an additional$18.9 billion in 2022. It's a much different story today. Pfizer has lost more than half of ...